Ensign Peak Advisors’s Eledon Pharmaceuticals ELDN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $3.43M | Hold |
1,264,919
| – | – | 0.01% | 730 |
|
|
2025
Q1 | $4.29M | Hold |
1,264,919
| – | – | 0.01% | 668 |
|
|
2024
Q4 | $5.21M | Buy |
1,264,919
+821,918
| +186% | +$3.39M | 0.01% | 636 |
|
|
2024
Q3 | $1.1M | Hold |
443,001
| – | – | ﹤0.01% | 1260 |
|
|
2024
Q2 | $1.17M | Hold |
443,001
| – | – | ﹤0.01% | 1185 |
|
|
2024
Q1 | $913K | Hold |
443,001
| – | – | ﹤0.01% | 1388 |
|
|
2023
Q4 | $797K | Hold |
443,001
| – | – | ﹤0.01% | 1506 |
|
|
2023
Q3 | $607K | Hold |
443,001
| – | – | ﹤0.01% | 1525 |
|
|
2023
Q2 | $607K | Hold |
443,001
| – | – | ﹤0.01% | 1570 |
|
|
2023
Q1 | $1.05M | Hold |
443,001
| – | – | ﹤0.01% | 1199 |
|
|
2022
Q4 | $1.03M | Buy |
443,001
+355,715
| +408% | +$825K | ﹤0.01% | 1134 |
|
|
2022
Q3 | $241K | Buy |
87,286
+10,186
| +13% | +$28.1K | ﹤0.01% | 1796 |
|
|
2022
Q2 | $188K | Hold |
77,100
| – | – | ﹤0.01% | 1812 |
|
|
2022
Q1 | $304K | Hold |
77,100
| – | – | ﹤0.01% | 1748 |
|
|
2021
Q4 | $340K | Buy |
77,100
+69,872
| +967% | +$308K | ﹤0.01% | 1769 |
|
|
2021
Q3 | $45K | Sell |
7,228
-28,883
| -80% | -$180K | ﹤0.01% | 1835 |
|
|
2021
Q2 | $286K | Hold |
36,111
| – | – | ﹤0.01% | 1682 |
|
|
2021
Q1 | $386K | Hold |
36,111
| – | – | ﹤0.01% | 1636 |
|
|
2020
Q4 | $556K | Hold |
36,111
| – | – | ﹤0.01% | 1581 |
|
|
2020
Q3 | $618K | Buy |
+36,111
| New | +$618K | ﹤0.01% | 1475 |
|